Low‐rank fusion convolutional neural network for prediction of remission after stereotactic radiosurgery in patients with acromegaly: a proof‐of‐concept study

• Published in: The Journal of pathology 2022-09, Vol.258 (1), p.49-57
• Main Authors: Qiao, Nidan, Yu, Damin, Wu, Guoqing, Zhang, Qilin, Yao, Boyuan, He, Min, Ye, Hongying, Zhang, Zhaoyun, Wang, Yongfei, Wu, Hanfeng, Zhao, Yao, Yu, Jinhua
• Format: Article
• Language: English
• Subjects: Acromegaly; Artificial intelligence; Decision making; Gamma knife; growth hormone; multicenter; neural network; Neural networks; pathomic; Patients; Pituitary; pituitary adenoma; Radiosurgery; Remission; Sensitivity analysis
• ISSN: 0022-3417; 1096-9896
• DOI: 10.1002/path.5974

Artificial intelligence approaches to analyze pathological images (pathomic) for outcome prediction have not been sufficiently considered in the field of pituitary research. A total of 5,504 hematoxylin & eosin‐stained pathology image tiles from 58 acromegalic patients with a good or poor outcome were integrated with other clinical and genetic information to train a low‐rank fusion convolutional neural network (LFCNN). The model was externally validated in 1,536 patches from an external cohort. The primary outcome was the time to the first endocrine remission after stereotactic radiosurgery (SRS). The median time of initial endocrine remission was 43 months (interquartile range [IQR]: 13–60 months) after SRS, and the 24‐month initial cumulative remission rate was 57.9% (IQR: 46.4–72.3%). The patient‐wise accuracy of the LFCNN model in predicting the primary outcome was 92.9% in the internal test dataset, and the sensitivity and specificity were 87.5 and 100.0%, respectively. The LFCNN model was a strong predictor of initial cumulative remission in the training cohort (hazard ratio [HR] 9.58, 95% confidence interval [CI] 3.89–23.59; p